Polar Asset Management Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Polar Asset Management Partners’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9,900	Closed	-$2.29M	–	845
2023 Q4	$2.29M	Sell	9,900 -400	-4%	-$70K	0.04%	356
2023 Q3	$1.5M	Sell	10,300 -5,400	-34%	-$1.02M	0.03%	424
2023 Q2	$3.63M	Buy	15,700 +11,800	+303%	+$3.2M	0.07%	364
2023 Q1	$945K	Hold	3,900	–	–	0.01%	584
2022 Q4	$1.13M	Buy	+3,900	New	+$381K	0.01%	680
2022 Q2	–	Sell	-52,800	Closed	-$5.18M	–	1392
2022 Q1	$5.18M	Hold	52,800	–	–	0.06%	413
2021 Q4	$4.47M	Hold	52,800	–	–	0.05%	446
2021 Q3	$4.21M	Buy	52,800 +24,700	+88%	+$2.13M	0.04%	445
2021 Q2	$2.74M	Buy	+28,100	New	+$3.33M	0.03%	511

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Polar Asset Management Partners's MDGL Position: Q1 2024 in Review

Polar Asset Management Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2024, closing a stake of 9,900 shares — an estimated $2.29M sold.

Polar Asset Management Partners first reported a position in MDGL in Q2 2021 and held it in 9 quarters. The position peaked at $5.18M in Q1 2022. 268 funds tracked by Wall St. Rank hold MDGL as of Q1 2024.

Polar Asset Management Partners reported no remaining Madrigal Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Polar Asset Management Partners sold 9,900 Madrigal Pharmaceuticals shares in Q1 2024, an estimated $2.29M.
Polar Asset Management Partners first reported a position in Madrigal Pharmaceuticals in Q2 2021 and held it in 9 quarters.
Polar Asset Management Partners's Madrigal Pharmaceuticals position peaked at $5.18M in Q1 2022.
268 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2024.

Based on Polar Asset Management Partners's 13F filing for Q1 2024, filed 15 May 2024.